Accelerating drug discovery to transform patients' lives Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com Biopharmaceuticals, Orphan Disease Therapeutics, Rare Diseases, and Serious Diseases

610 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Innovation in medical needs. Inmedical Therapeutics es un fabricante de productos médicos y soluciones en formato hidrogel ubicado en Vitoria. Biotecnología, Endoscopia, Farmacéutica, and Producto Médico

126 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Integrated Drug Discovery | Drug Development | Contract Research Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development. biotechnology, pharmaceuticals, drug discovery, preclinical research, bioanalytical development services, bioinformatics, systems biology, proteins, genomics, proteomics, autoimmune disorders, regulatory studies, medicinal chemistry, agrochemical, industrial chemistry, and assay development&screening

504 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

A clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies. Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. Our research and development programs target indications with substantial unmet medical needs: NASH, MPS and oncology. Drug Discovery, Biotech, Oncology, Fibrosis, Lysosomal Storage Disorders, NASH, and SSc

154 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Improving the lives of patients with next generation therapies for cancer and respiratory disease, including COVID-19. APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies. Our company has a well balanced portfolio with one product on the market and several promising products from clinical to pre-clinical stages. As for the product on the market, APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients. We out-licensed Qarziba® globally to EUSA Pharma …

9 similar entities Type: SMB Activities: biotech deeptech

Regenerative Medicine - Growth Disregulation - Oncology REGULAXIS is a French innovative biotechnology company based at BIOCITECH the technology park of life science of Paris North area. The company is engaged in the research, development and licensing of innovative synthetic molecules for use in human therapies. Its mission is to grant licenses of innovative molecules in a pharmaceutical company after the establishment of a phase II clinical record. REGULAXIS leads its R&D on its own premises, particularly in regard to biochemical and biological experiments, and keeps the mastery of the chemical synthesis of its therapeutic molecules. The company develops its …

250 similar entities Type: Startup Activities: biotech healthtech Technologies: Synthetic Biology

Innovation in Marine-Derived Oncology Therapies Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin. PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other …

89 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

A Biotech Company 100% Focused On Advancing New Therapies For Childhood Cancer A life science company exclusively focused on finding cures for childhood cancer by identifying and developing the most promising projects to create new treatments and drugs. drug development, clinical development, and childhood cancer

297 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Medicine Maker celebrates the people, processes and vision that bring new drugs and biologics to market. The development and manufacture of new drugs and biological medicines draws on the talent, passion and experience of a wide range of professionals. The goal of The Medicine Maker is to bring this group into the limelight and, in doing so, to integrate the entire process, from the registration of an Investigational New Drug (IND) or Biologics License Application (BLA) through to the market launch of new therapies, and beyond. pharmaceutical , biopharmaceutical, bioprocess, upstream, downstream, formulation, drug delivery, and dosage form

137 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine

576 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Our vision: To profoundly impact the lives of patients with orphan diseases and their families Orphazyme is a global biopharmaceutical company, headquartered in Denmark, with a rapidly growing presence in the United States. We are pioneering a new kind of treatment, applying our specialized expertise to bring innovative therapies to patients with neurodegenerative orphan diseases. With a late-stage drug pipeline, we are relentless in our commitment to advancing treatments and making a profound impact for those touched by these rare, serious diseases. Today we are listed on Nasdaq Copenhagen (TICKER: ORPHA.CO) and Nasdaq U.S. (TICKER: ORPH), and are expanding our …

23 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

New treatments for central nervous system disorders Neurolixis Inc. is a biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of human central nervous system diseases including movement disorders, autism spectrum disorders, depression and pain. Neuroscience, Drug development, Rett Syndrome, Parkinson's disease, Biased agonism, and Orphan Drug

140 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

NEW FRONTIERS IN NEUROSCIENCE Expertise, Experience, Innovation, Vision, Values. Neurentis PLC is a late-clinical stage UK biotech company, focusing on neuroscience and specialising in the development of novel treatments for mental health and other neurological and psychiatric diseases. Our product pipeline is balanced with 3 products: 1) an advanced lead drug candidate, a prescription pharmaceutical (selegiline), in a transdermal patch, for the treatment of Treatment-Resistant Depression (TRD) in the last stages of drug development, 2) a small molecule agonist of the oxytocin receptors for the treatment of Autism, Chronic and Neuropathic Pain and addiction to alcohol and opioids and 3) …

100 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Innovating to Disrupt Cancer Treatment Genoscience Pharma is a French biotech company developing unique small molecules in Oncology. This is the first clinical stage company ever with unique lysosomotropic agents assessed in global clinical trials. For more information, please visit our website, or call us +33 4 91 26 99 50. Liver, Oncology, Clinical Development, Preclinical Development, Discovery, Research & Development, Intellectual Property, Drug Development, and Small Molecule

198 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Novel small-molecule drugs in immunology, fibrosis and women health Clinical-stage biotech company founded by serial entrepreneurs and owned by private & institutional investors. Discovery and development of new chemical entities with strong IP and worldwide rights targeting indications with high unmet medical need in immunology, fibrosis and women health. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, Inflammation and autoimmune diseases, IP generation, IBD, Ulcerative Colitis, Crohn's disease, Fibrosis, and Uterine fibroids

252 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering DARPin Therapeutics for Patients Molecular Partners AG is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics, a new class of custom-built drugs for medical challenges other modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zürich, Switzerland and Concord, MA, USA. DARPins, Oncology, Immuno-Oncology, Radiopharmaceuticals, …

80 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology